245 related articles for article (PubMed ID: 1569445)
1. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer.
Rothenberg ML; Ozols RF; Glatstein E; Steinberg SM; Reed E; Young RC
J Clin Oncol; 1992 May; 10(5):727-34. PubMed ID: 1569445
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.
Grem J; O'Dwyer P; Elson P; Simon N; Trump D; Frontiera M; Falkson G; Vogl S
J Clin Oncol; 1991 Oct; 9(10):1793-800. PubMed ID: 1919629
[TBL] [Abstract][Full Text] [Related]
3. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA
J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
[TBL] [Abstract][Full Text] [Related]
4. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
Swenerton K; Jeffrey J; Stuart G; Roy M; Krepart G; Carmichael J; Drouin P; Stanimir R; O'Connell G; MacLean G
J Clin Oncol; 1992 May; 10(5):718-26. PubMed ID: 1569444
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin and cyclophosphamide in advanced ovarian carcinoma: activity and toxicity of an ambulatory regimen.
Zambetti M; Gianni L; Di Re F; Spatti G; Fontanelli R; Escobedo A; De Palo G; Bonadonna G
Am J Clin Oncol; 1990 Jun; 13(3):199-203. PubMed ID: 2161174
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
[TBL] [Abstract][Full Text] [Related]
9. Sequential cisplatin/cyclophosphamide chemotherapy and abdominopelvic radiotherapy in the management of advanced ovarian cancer.
Green JA; Warenius HM; Errington RD; Myint S; Spearing G; Slater AJ
Br J Cancer; 1988 Nov; 58(5):635-9. PubMed ID: 3219276
[TBL] [Abstract][Full Text] [Related]
10. High-dose, short-duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancer.
Hunter RE; Griffin TW; Stevens S; Roman LD; Bokhari F; Reale FR; Tak WK; Fitzgerald TJ; Dillon MB; Rose PG
Cancer; 1991 Nov; 68(9):1890-4. PubMed ID: 1655227
[TBL] [Abstract][Full Text] [Related]
11. Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer.
Beller U; Speyer J; Colombo N; Sorich J; Wernz J; Hochster H; Zeleniuch-Jacquotte A; Porges R; Beckman EM
J Clin Oncol; 1991 May; 9(5):809-17. PubMed ID: 2016624
[TBL] [Abstract][Full Text] [Related]
12. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.
Hakes TB; Chalas E; Hoskins WJ; Jones WB; Markman M; Rubin SC; Chapman D; Almadrones L; Lewis JL
Gynecol Oncol; 1992 Jun; 45(3):284-9. PubMed ID: 1612505
[TBL] [Abstract][Full Text] [Related]
13. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.
Wils J; Blijham G; Naus A; Belder C; Boschma F; Bron H; Ceelen T; Eekhout A; von Erp J; Geelen P
J Clin Oncol; 1986 Jul; 4(7):1068-73. PubMed ID: 3723166
[TBL] [Abstract][Full Text] [Related]
14. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma.
Piver MS; Lele SB; Marchetti DL; Baker TR; Emrich LJ; Hartman AB
J Clin Oncol; 1988 Nov; 6(11):1679-84. PubMed ID: 3183700
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.
Lévi F; Benavides M; Chevelle C; Le Saunier F; Bailleul F; Misset JL; Regensberg C; Vannetzel JM; Reinberg A; Mathé G
J Clin Oncol; 1990 Apr; 8(4):705-14. PubMed ID: 2179481
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin and cyclophosphamide in early epithelial ovarian carcinoma.
Chiara S; Conte PF; Bruzzone M; Falcone A; Sertoli MR; Carnino F; Mossetti C; Iura R; Durando C; Guercio E
Chemioterapia; 1987 Oct; 6(5):380-3. PubMed ID: 3427698
[TBL] [Abstract][Full Text] [Related]
17. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
Sutton GP; Stehman FB; Einhorn LH; Roth LM; Blessing JA; Ehrlich CE
J Clin Oncol; 1989 Feb; 7(2):223-9. PubMed ID: 2915238
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.
Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Willemse PH; Heintz AP; van Lent M; Trimbos JB; Bouma J; Vermorken JB
J Clin Oncol; 1987 Aug; 5(8):1157-68. PubMed ID: 3114434
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin/cyclophosphamide combination chemotherapy for advanced ovarian cancer.
Teeling M; Hayes Y; Fitzmaurice B; McGing P; Carney DN
Semin Oncol; 1992 Feb; 19(1 Suppl 2):102-6. PubMed ID: 1411620
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.
Omura GA; Bundy BN; Berek JS; Curry S; Delgado G; Mortel R
J Clin Oncol; 1989 Apr; 7(4):457-65. PubMed ID: 2926470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
